Bionano Genomics appoints Alex Hastie as Chief Scientific Officer to lead global scientific strategy.

Bionano Genomics has named Alex Hastie, Ph.D., as its new Chief Scientific Officer effective July 20, 2026. Hastie, a key figure in developing Bionano's optical genome mapping technology, will drive the company's scientific innovation and clinical research strategy. His return is expected to strengthen global collaborations and accelerate the adoption of genome analysis technologies in clinical research. Industry experts praise his leadership and anticipate expanded applications in genomics and oncology.